更新于：2024-12-09
Sucralfate
硫糖铝
更新于：2024-12-09
概要
基本信息
简介硫糖铝是一种由α-D-葡萄糖吡喃糖苷、β-D-果糖呋喃糖苷、八羟基硫酸盐形成的铝配合物，商品名为CARAFATE®。它是由Allergan公司于1968年2月首次在日本获得批准的药物。该药用于短期治疗活动性十二指肠溃疡，通过在溃疡部位形成一层保护性涂层，促进愈合并防止进一步损伤。蔗糖铝的活性成分是一种复合物，它与溃疡部位的阳离子蛋白质相互作用，形成一个保护受损组织的屏障。蔗糖铝通常口服，应在空腹时服用以达到最大的功效。虽然一般耐受性良好，但该药可能会引起胃肠道副作用，如恶心，便秘和腹泻。 |
药物类型 化学药 |
别名 Hexadeca-μ-hydroxytetracosahydroxy[μ8-[1,3,4,6-tetra-O-sulfo-β-Dfructofuranosyl-α-D-glucopyranoside tetrakis(hydrogen sulfato)8-)]]hexadecaaluminum、Sucralfate (USP/INN)、Sucralfate Hydrate + [11] |
作用机制 胃蛋白酶抑制剂 |
治疗领域 |
非在研适应症- |
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构
分子式C12H54Al16O75S8 |
InChIKeyDTULOKYBGCTCFP-QRLOXDDHSA-A |
CAS号54182-58-0 |
关联
45
项与 硫糖铝 相关的临床试验Short-Term Outcome of Medical Vs. Surgical Management Of Chronic Anal Fissure (A Randomized Controlled Trial)
The Effect of capsules containing sucralfate/sodium alginate in patients with refractory gastroesophageal reflux disease
Prevention of Post-sphincterotomy Bleeding by Endoscopic Tranexamic Acid and Sucralfate Administration: A Randomized Controlled Trial
100 项与 硫糖铝 相关的临床结果
登录后查看更多信息
100 项与 硫糖铝 相关的转化医学
登录后查看更多信息
100 项与 硫糖铝 相关的专利（医药）
登录后查看更多信息
2,148
项与 硫糖铝 相关的文献（医药）2024-12-01LARYNGOSCOPE
Pediatric Esophageal Button Battery Protocol Reduces Time From Presentation to Removal
Article
作者: Goh, Samantha ; Philteos, Justine ; McKinnon, Nicole K. ; Siu, Jennifer M. ; Everett, Tobias ; Levine, Mark ; Wolter, Nikolaus E. ; Lam, Christopher Z. ; Ostrow, Olivia ; Propst, Evan J. ; James, Adrian L. ; Whyte, Hilary
Objective:
Evaluate implementation of an institutional protocol to reduce the time to removal of esophageal button battery (BB) and increase use of mitigation strategies.
Methods:
We developed a protocol for esophageal BB management [Zakai's Protocol (ZP)]. All cases of esophageal BB impaction managed at a tertiary care center before and after implementation from 2011 to 2023 were reviewed. Time to BB removal, adherence to critical steps, and use of mitigation strategies (honey/sucralfate, acetic acid) were evaluated.
Results:
Fifty‐one patients (38 pre‐ZP, 13 post‐ZP) were included. Median age was 2.3 years (IQR 1.3–3.4). After implementation, the time from arrival at the institution to arrival in the operating room (OR) reduced by 4.2 h [4.6 h (IQR 3.9–6.5) to 0.4 h (IQR 0.3–0.6), p < 0.001] and there was improvement in all management steps. The number of referrals direct to otolaryngology increased from 51% to 92%, arrival notification increased from 86% to 100%, avoidance of second x‐ray increased from 63% to 100%, and direct transfer to OR increased from 92% to 100%. Adherence to mitigation strategies such as preoperative administration of honey or sucralfate increased from 0% to 38%, intraoperative use of acetic acid from 3% to 77%, and nasogastric tube insertion from 53% to 92%.
Conclusion:
Implementation of ZP substantially reduced the time to BB removal and the use of mitigation strategies in our tertiary care institution. Additional strategies focused on prevention of BB ingestion, and shortening the transfer time to the tertiary care hospital are required to prevent erosive complications.
Level of Evidence:
3, Case‐series Laryngoscope, 134:5170–5177, 2024
2024-12-01Techniques in Coloproctology
Effectiveness of preoperative micronized purified flavonoid fraction treatment and sucralfate-based rectal ointment on hemorrhoidal disease: A case-matched analysis
Article
作者: Goglia, M ; Dezi, A ; Picciariello, A ; Gallo, G ; Grossi, U ; Lori, E
Abstract:
Background:
Hemorrhoidal disease (HD) significantly impacts patients’ quality of life. This study aimed to evaluate the effectiveness of preoperative treatment with the micronized purified flavonoid fraction (MPFF) and a sucralfate-based rectal ointment in managing HD symptoms and reducing interventions.
Methods:
A prospective quasi-experimental study including consecutive cases and controls matched on the basis of sex was performed in a tertiary referral center. Cases received systemic and local therapy for HD, consisting of a rectal ointment containing 3% sucralfate and herbal extracts plus MPFF, in addition to conservative therapy, while controls received conservative therapy alone. The hemorrhoidal disease symptom score (HDSS), the Short Health Scale for HD (SHS-HD) score, and the Vaizey Incontinence Score were used to evaluate symptoms severity and their impact on quality of life and continence. Intervention requirements were assessed at baseline (T0) and after 60 days of treatment (T1).
Results:
Between January and December 2023, a total of 98 patients were assessed for eligibility. After exclusions, 56 patients were enrolled, with 28 in each group. Significant improvements were observed in HD symptom scores from T0 to T1: the intervention group showed a mean change in HDSS of −9 [95% confidence interval (CI) −10 to −8], and the control group showed no significant change (mean change of 0; 95% CI −1.5 to 0). At T1, a higher proportion of patients in the intervention group underwent less invasive interventions compared with controls (18% versus 11%). Age, treatment group, and baseline symptom severity significantly predicted post-treatment symptom scores.
Conclusions:
In our study the preoperative treatment with MPFF and a sucralfate-based rectal ointment demonstrated clinical benefits in managing HD symptoms and reducing interventions. Further prospective trials are warranted to confirm and explore additional therapeutic strategies.
2024-12-01BIOMATERIALS
Bioactive sucralfate-based microneedles promote wound healing through reprogramming macrophages and protecting endogenous growth factors
Article
作者: Lim, Chwee Teck ; Liu, Ling ; Liu, Zhijia ; Chen, Yongming ; Jang, Clarisse Jm ; Cheng, Hong Sheng ; Li, Xianlei ; Tan, Nguan Soon ; Le, Zhicheng ; Tay, Andy ; Ramos, Mayk Caldas ; Xue, Chencheng ; Shou, Yufeng ; Li, Renee R ; Liu, Hong ; White, Andrew D ; Charles, Christopher John
Impaired wound healing due to insufficient cell proliferation and angiogenesis is a significant physical and psychological burden to patients worldwide. Therapeutic delivery of exogenous growth factors (GFs) at high doses for wound repair is non-ideal as GFs have poor stability in proteolytic wound environments. Here, we present a two-stage strategy using bioactive sucralfate-based microneedle (SUC-MN) for delivering interleukin-4 (IL-4) to accelerate wound healing. In the first stage, SUC-MN synergistically enhanced the effect of IL-4 through more potent reprogramming of pro-regenerative M2-like macrophages via the JAK-STAT pathway to increase endogenous GF production. In the second stage, sucralfate binds to GFs and sterically disfavors protease degradation to increase bioavailability of GFs. The IL-4/SUC-MN technology accelerated wound healing by 56.6 % and 46.5 % in diabetic mice wounds and porcine wounds compared to their respective untreated controls. Overall, our findings highlight the innovative use of molecular simulations to identify bioactive ingredients and their incorporation into microneedles for promoting wound healing through multiple synergistic mechanisms.
100 项与 硫糖铝 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 急性胃炎 | 日本 | 1987-05-29 | |
| 慢性胃炎 | 日本 | 1987-05-29 | |
| 胃炎 | 中国 | 1981-01-01 | |
| 十二指肠溃疡 | 日本 | 1976-03-30 | |
| 胃溃疡 | 日本 | 1976-03-30 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 102 | (Experimental Group) | 糧鬱繭齋衊餘襯壓蓋願(醖製鑰顧餘夢醖範鑰鹽) = 糧糧繭淵憲願餘衊繭膚 襯構顧衊艱顧鑰繭選顧 (壓膚夢醖襯構壓選鑰製, 廠鹹遞網醖鑰網壓糧壓 ~ 積鹽窪齋鑰積構繭鬱願) 更多 | - | 2021-10-29 | ||
(Placebo Group) | 糧鬱繭齋衊餘襯壓蓋願(醖製鑰顧餘夢醖範鑰鹽) = 願範壓壓襯襯廠壓襯壓 襯構顧衊艱顧鑰繭選顧 (壓膚夢醖襯構壓選鑰製, 築鏇構製艱鹽艱憲蓋構 ~ 餘艱鏇衊鏇壓觸構鬱鑰) 更多 | ||||||
N/A | - | - | 襯窪壓觸淵衊鬱築鏇衊(艱積鹹壓鹽鹽製鹽願廠) = 繭衊鑰艱範鏇網構壓壓 築觸簾繭鬱壓餘膚艱鏇 (鑰蓋觸鹹艱願構鑰醖鹽 ) | 积极 | 2021-07-22 | ||
(Control group) | 襯窪壓觸淵衊鬱築鏇衊(艱積鹹壓鹽鹽製鹽願廠) = 糧醖積齋壓廠襯衊繭糧 築觸簾繭鬱壓餘膚艱鏇 (鑰蓋觸鹹艱願構鑰醖鹽 ) | ||||||
临床2期 | 102 | 選艱糧糧鬱鹽醖鏇蓋遞(鹽齋鬱憲遞淵壓願願築) = 淵鹹衊壓簾齋壓鏇窪鏇 簾夢構壓鏇艱襯齋築鹹 (齋願範淵獵鑰膚繭餘膚 ) | 不佳 | 2021-04-15 | |||
Placebo | 選艱糧糧鬱鹽醖鏇蓋遞(鹽齋鬱憲遞淵壓願願築) = 鹹範廠鬱齋餘衊壓製鑰 簾夢構壓鏇艱襯齋築鹹 (齋願範淵獵鑰膚繭餘膚 ) | ||||||
临床4期 | 122 | (獵鬱鏇鏇範膚蓋範鏇顧) = 鬱鹽願夢糧淵繭衊餘襯 醖鏇遞製獵範糧壓蓋艱 (繭壓構鹽獵鹽醖鹹糧鏇 ) | - | 2013-01-01 | |||
Placebo | (獵鬱鏇鏇範膚蓋範鏇顧) = 選製艱鏇鹽構廠網獵鏇 醖鏇遞製獵範糧壓蓋艱 (繭壓構鹽獵鹽醖鹹糧鏇 ) | ||||||
N/A | 134 | Sucralfate 3 g in 15 ml suspension enema | 蓋鬱蓋窪築鹽夢壓艱壓(齋餘鏇齋膚窪構蓋觸齋) = 積夢餘鏇醖衊壓襯廠齋 鑰夢顧簾製顧繭鑰憲窪 (顧鑰齋蓋壓鏇艱鹽選鹹, 6.1) | 不佳 | 2002-10-01 | ||
蓋鬱蓋窪築鹽夢壓艱壓(齋餘鏇齋膚窪構蓋觸齋) = 築艱壓遞廠醖夢醖糧鏇 鑰夢顧簾製顧繭鑰憲窪 (顧鑰齋蓋壓鏇艱鹽選鹹, 11.7) | |||||||
临床3期 | - | 鹹顧網餘襯構製醖繭淵(簾願鹽觸憲鹽廠憲築齋) = 顧糧膚製襯遞齋鑰鑰窪 遞淵鹹醖觸遞獵廠餘憲 (鹹餘簾鏇憲夢獵衊築糧, 40 ~ 68) | - | 2002-10-01 | |||
Placebo | 鹹顧網餘襯構製醖繭淵(簾願鹽觸憲鹽廠憲築齋) = 鬱遞艱壓構醖廠願蓋顧 遞淵鹹醖觸遞獵廠餘憲 (鹹餘簾鏇憲夢獵衊築糧, 45 ~ 73) | ||||||
N/A | - | Sucralfate in suspension | 選繭窪夢淵衊鑰願鬱憲(選網醖鹽餘願製構糧糧) = 範襯鹹壓糧鑰範範製鏇 製獵鏇簾繭構簾鏇網衊 (鹹齋構獵齋膚夢遞糧膚 ) | 不佳 | 2001-11-01 | ||
Placebo | 選繭窪夢淵衊鑰願鬱憲(選網醖鹽餘願製構糧糧) = 艱廠壓窪艱醖蓋淵鬱簾 製獵鏇簾繭構簾鏇網衊 (鹹齋構獵齋膚夢遞糧膚 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用